文献速递类风湿关节炎

类风湿关节炎中JAK抑制剂减量与原剂量比较的倾向评分匹配真实世界研究

Reduced versus standard dosing of Janus kinase inhibitors in rheumatoid arthritis: a propensity score-matched real-world study accounting for poor prognostic factors.
PubMed 文献 · Ann Rheum Dis · 2026-04-28

该多中心观察性研究基于日本真实世界注册数据库,纳入2013至2025年间启动JAK抑制剂(JAKi)的1135例类风湿关节炎(RA)患者,采用倾向评分匹配比较标准剂量与减量起始的24个月药物留存率。在肾功能保留患者中,减量起始与标准剂量的24个月治疗持续性相当,疾病活动度改善相似且糖皮质激素使用未增加;但在多重不良预后因素(PPF)负担或肾功能减退患者中,标准剂量起始显示更有利的持续性。

要点

  • 肾功能保留的RA患者中,减量JAKi起始的24个月药物留存与标准剂量相当。
  • PPF负担高或肾功能减退者,标准剂量起始的持续治疗更有利。
  • 减量组疾病活动度改善与标准剂量相似,未出现糖皮质激素补偿性增加。

核心结论

  • 在肾功能保留的RA患者中,减量JAKi起始与标准剂量起始的24个月治疗持续性相当。
  • PPF分层及肾功能减退患者的分析结果需谨慎解读,有待进一步研究。

研究设计与样本

  • 多中心观察性研究,使用日本真实世界注册数据库中2013至2025年启动JAKi的RA患者。
  • 共纳入1135例患者,按初始JAKi剂量策略分类,主要分析限于肾功能保留患者。
  • 采用倾向评分匹配校正适应证混杂,以Kaplan-Meier分析和Cox比例风险模型评估24个月药物留存。

主要发现

  • 在肾功能保留的匹配队列中,标准剂量与减量JAKi的24个月药物留存相当。
  • 两组疾病活动度改善相似,糖皮质激素使用保持较低水平且无补偿性增加。
  • PPF负担低(0-2)患者中减量表现相当,而多重PPF(3-4)患者中标准剂量起始持续性更有利。
  • 肾功能减退患者中,标准剂量与更高的药物留存相关。

临床怎么用

  • 肾功能保留且PPF负担低的RA患者可考虑减量JAKi起始,其24个月持续性与标准剂量相当。
  • PPF负担多重或肾功能减退的RA患者,标准剂量JAKi起始可能更有利于治疗持续性。

局限性

  • PPF分层分析和肾功能减退患者的结果应谨慎解读,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to compare 24-month drug retention between standard-dose and reduced-dose Janus kinase inhibitors (JAKi) in rheumatoid arthritis (RA) and to examine whether poor prognostic factor (PPF) burden and renal function modify treatment persistence, with primary inference restricted to patients with preserved renal function, in whom reduced dosing reflects discretionary clinical decision-making. METHODS: We conducted a multicentre observational study using a Japanese real-world registry of patients with RA who initiated JAKi between 2013 and 2025. Patients were classified according to their initial JAKi dosing strategy. Primary analyses were performed in patients with preserved renal function. Propensity score matching was used to adjust for confounding by indication. Drug retention over 24 months was assessed using Kaplan-Meier analyses and Cox proportional hazards models, with prespecified stratification by PPF burden (0-2 vs 3-4). Supportive analyses were conducted in patients with reduced renal function. RESULTS: Among 1135 patients, 24-month drug retention was comparable between standard-dose and reduced-dose JAKi in the matched cohort with preserved renal function. Disease activity improved similarly in both groups, and glucocorticoid use remained low without compensatory escalation. Reduced dosing performed comparably in patients with low PPF burden, whereas standard-dose initiation showed more favourable persistence in patients with multiple PPFs. In patients with reduced renal function, standard dosing was associated with higher drug retention. CONCLUSIONS: In patients with preserved renal function, reduced-dose JAKi initiation was associated with 24-month treatment persistence comparable with standard dosing. Findings in PPF-stratified analyses and in patients with reduced renal function should be interpreted cautiously and warrant further investigation.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Nozaki Y, Shiga T, Ri J, et al. Reduced versus standard dosing of Janus kinase inhibitors in rheumatoid arthritis: a propensity score-matched real-world study accounting for poor prognostic factors. Ann Rheum Dis. 2026. PMID: 42049606. doi:10.1016/j.ard.2026.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。